Litcius/Paper detail

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, Froylán López López, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip

2022The Lancet Respiratory Medicine222 citationsDOI

Topics & Concepts

MedicineCrizotinibClinical endpointInterim analysisInternal medicineProgression-free survivalLung cancerOncologyResponse Evaluation Criteria in Solid TumorsSurrogate endpointHazard ratioAnaplastic lymphoma kinaseCancerSurgeryPhases of clinical researchConfidence intervalRandomized controlled trialClinical trialChemotherapyMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study | Litcius